Patents Assigned to Japan as Represented by the Director-General of National Institute of Infections Diseases
  • Publication number: 20220409594
    Abstract: CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 29, 2022
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIONS DISEASES
    Inventors: Shuzo MATSUSHITA, Kazuhisa YOSHIMURA, Hirokazu TAMAMURA, Ami MASUDA, Kohei TAKAHASHI, Takuya KOBAYAKAWA, Shigeyoshi HARADA, Tomoyuki MIURA
  • Patent number: 8795687
    Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 5, 2014
    Assignees: Japan as Represented by the Director-General of National Institute of Infections Diseases, The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Asato Kojima, Hidehiro Takahashi, Toyokazu Ishikawa